PS
RIGL icon

Principal Securities’s Rigel Pharmaceuticals RIGL Stock Holding History

Principal Securities’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-211
Closed -$1.73K – 3527
2024
Q2 		$1.73K Hold
211
– – ﹤0.01% 2950
2024
Q1 		$3.12K Hold
211
– – ﹤0.01% 2752
2023
Q4 		$3.06K Buy
+211
New +$2.16K ﹤0.01% 2696

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Principal Securities's RIGL Position: Q3 2024 in Review

Principal Securities sold out of Rigel Pharmaceuticals (RIGL) in Q3 2024, closing a stake of 211 shares — an estimated $1.73K sold.

Principal Securities first reported a position in RIGL in Q4 2023 and held it in 3 quarters. The position peaked at $3.12K in Q1 2024. 93 funds tracked by Wall St. Rank hold RIGL as of Q3 2024.

  • Principal Securities reported no remaining Rigel Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Principal Securities sold 211 Rigel Pharmaceuticals shares in Q3 2024, an estimated $1.73K.
  • Principal Securities first reported a position in Rigel Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Principal Securities's Rigel Pharmaceuticals position peaked at $3.12K in Q1 2024.
  • 93 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2024.

Based on Principal Securities's 13F filing for Q3 2024, filed 28 Oct 2024.